Progenics Pharmaceuticals (PGNX) Upgraded to “Buy” by BidaskClub
BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.
A number of other research analysts have also commented on the company. Zacks Investment Research lowered Progenics Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, November 8th. Cantor Fitzgerald reissued a buy rating and set a $15.00 price target on shares of Progenics Pharmaceuticals in a report on Thursday, November 2nd. Finally, ValuEngine raised Progenics Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Progenics Pharmaceuticals has a consensus rating of Buy and an average target price of $12.35.
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) traded up $0.24 on Thursday, reaching $6.93. The company had a trading volume of 231,898 shares, compared to its average volume of 1,198,070. Progenics Pharmaceuticals has a 52-week low of $4.60 and a 52-week high of $11.72. The company has a market capitalization of $470.11, a PE ratio of -8.56 and a beta of 3.12. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/03/05/progenics-pharmaceuticals-pgnx-upgraded-to-buy-by-bidaskclub.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.